circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== Structure == Factor VIII protein consists of six domains: A1-A2-B-A3-C1-C2, and is homologous to factor V. The A domains are homologous to the A domains of the copper-binding protein ceruloplasmin. The C domains belong to the phospholipid-binding discoidin domain family, and the C2 domain mediate membrane binding. Activation of factor VIII to factor VIIIa is done by cleavage and release of the B domain. The protein is now divided to a heavy chain, consisting of the A1-A2 domains, and a light chain, consisting of the A3-C1-C2 domains. Both form non-covalently a complex in a calcium-dependent manner. This complex is the pro-coagulant factor VIIIa.
Many organisms have evolved to produce light in a range of colors. At the molecular level, the difference in color arises from the degree of conjugation of the molecule, when an electron drops down from the excited state to the ground state. Deep sea organisms have evolved to produce light to lure and catch prey, as camouflage, or to attract others. Some bacteria even use bioluminescence to communicate. The common colors for the light emitted by these animals are blue and green because they have shorter wavelengths than red and can transmit more easily in water. In April 2020, researchers reported having genetically engineered plants glow much brighter than previously possible by inserting genes of the bioluminescent mushroom Neonothopanus nambi. The glow is self-sustained, works by converting plants' caffeic acid into luciferin and, unlike for bacterial bioluminescence genes used earlier, has a relatively high light output that is visible to the naked eye. Chemiluminescence is different from fluorescence. Hence, fluorescent proteins such as green fluorescent protein (GFP) are not chemiluminescent. However, combining GFP with luciferases allows bioluminescence resonance energy transfer (BRET), which increases the quantum yield of light emitted in these systems.
Miriam Luke. President, Henley Rowing Club and lately Chair, Henley Women's Regatta. For services to Women's Rowing. Martin Edward Machray. Executive Director of Performance, NHS England, London. For services to Healthcare. Malcolmina Mackay Macleod. Social and Health Carer. For services to the community of North Uist, Scotland. Professor Roma Maguire. Professor of Digital Health and Care, University of Strathclyde. For services to Health Care Research. Helen Ann Maitland. Lately National Director for Urgent and Unscheduled Care, Scottish Government. For services to NHS Scotland. Eric Malcomson. Founder and Chair, Tove Valley Broadband. For services to the community in the Tove Valley, Northamptonshire. Robert James Hammond Malcomson. Deputy Director, Cabinet Office. For public and voluntary service to the LGBTQ+ Community and to Homeless People. Sharon Manning. Cancer Nurse Specialist, Macmillan. For services to Cancer Patient Care. Deirdre Marshall. Team Leader, Ministry of Defence. For services to Defence. Kathryn Julia Marshall. Senior Manager, Lloyds Banking Group, Halifax. For services to Further Education and Skills. Robert James Martin. For services to Drama in Northern Ireland. Elsie Barbara Martlew. Lately Deputy Leader, City of Carlisle Council. For Political and Public Service. Paul Nicholas Martynenko. Vice-President, Registration and Standards, BCS, The Chartered Institute for IT. For services to the Information Technology Industry. Sarah Mason. Chief Executive Officer, Women's Aid Federation Northern Ireland. For services to Women and Girls.
==== Liquid-liquid extraction ==== Liquid-liquid extractions can be carried out on digital microfluidic device by taking advantage of immiscible liquids.9 Two droplets, one containing the analyte in aqueous phase, and the other an immiscible ionic liquid are present on the electrode array. The two droplets are mixed and the ionic liquid extracts the analyte, and the droplets are easily separable.
Sources: en.wikipedia.org
A cold trap is a concept in planetary science that describes an area cold enough to freeze (trap) volatiles. Cold traps can exist on the surfaces of airless bodies or in the upper layers of an adiabatic atmosphere. On airless bodies, the ices trapped inside cold traps can potentially remain there for geologic time periods, providing a glimpse into the primordial solar system. In adiabatic atmospheres, cold traps prevent volatiles (such as water) from escaping the atmosphere into space.
NH3 + hv → NH2 + H NH2 + CH4 → NH3 + CH3 NH2 + CH3 → CH5N CH5N + hv → HCN + 2H2 Other active intermediate compounds (acetylene, cyanoacetylene, etc.) have been detected in the aqueous solution of Miller–Urey-type experiments, but the immediate HCN and aldehyde production, the production of amino acids accompanying the plateau in HCN and aldehyde concentrations, and slowing of amino acid production rate during HCN and aldehyde depletion provided strong evidence that Strecker amino acid synthesis was occurring in the aqueous solution. Strecker synthesis describes the reaction of an aldehyde, ammonia, and HCN to a simple amino acid through an aminoacetonitrile intermediate:
=== Nutrition === Neon tetras are omnivores and will accept most flake foods, if sufficiently small, but should also have some small foods such as brine shrimp, daphnia, freeze-dried bloodworms, tubifex, which can be stuck to the side of the aquarium, and micropellet food to supplement their diets. A tropical sinking pellet is ideal, as most brands of these include natural color enhancers that bring out the color in neon tetras. Some frozen foods, including frozen blood worms, add variety to their diets.
Little Caesars produces a variety of pizzas. Several core menu items are part of the HOT-N-READY menu, designed to make popular items available for immediate carry-out, while others are considered either specialty pizzas or custom pizzas. In 2013, they added the Deep! Deep! Dish Pizza, a Detroit-style pizza, to the menu. Additional entrée options include flavored Caesar Wings and bread, such as Crazy Bread and Italian Cheese Bread. Select locations offer salads. All Little Caesars locations carry Pepsi products. Little Caesars also sells brownies. In 1996, they introduced Pizza by the Foot, a three-foot-long rectangular pizza. The product has since been discontinued; however, its equivalent, Pizza by the Meter, has been sold in the Saudi Arabian market since the 90s and is a top-rated product. On occasion, Little Caesars releases limited time offers. In 2014, they introduced the Soft Pretzel Crust Pizza, and in 2015, the "Bacon Wrapped Deep! Deep! Dish Pizza." In May 2019, Little Caesars began testing a pizza with meatless sausage made by Impossible Foods. In June 2020, Little Caesars reintroduced Stuffed Crazy Bread. They first introduced it in 1995. The original Crazy Bread was first introduced in 1982. As of May 15, 2023, Little Caesars introduced Crazy Puffs in Canada as a handheld snack made with pizza dough filled with cheese, pepperoni, and sauce, topped with garlic sauce and herbs. They later launched in the U.S. on March 11, 2024, offering both pepperoni and cheese varieties.
Traditional Malaysian art was mainly centred on the areas of carving, weaving, and silversmithing. Traditional art ranges from handwoven baskets from rural areas to the silverwork of the Malay courts. Common artworks included ornamental kris, beetle nut sets, and woven batik and songket fabrics. Indigenous East Malaysians are known for their wooden masks. Each ethnic group have distinct performing arts, with little overlap between them. However, Malay art does show some North Indian influence due to the historical influence of India. Traditional Malay music and performing arts appear to have originated in the Kelantan-Pattani region with influences from India, China, Thailand, and Indonesia. The music is based around percussion instruments, the most important of which is the gendang (drum). There are at least 14 types of traditional drums. Drums and other traditional percussion instruments and are often made from natural materials. Music is traditionally used for storytelling, celebrating life-cycle events, and occasions such as a harvest. It was once used as a form of long-distance communication. In East Malaysia, gong-based musical ensembles such as agung and kulintang are commonly used in ceremonies such as funerals and weddings. These ensembles are also common in neighbouring regions such as in Mindanao in the Philippines, Kalimantan in Indonesia, and Brunei. Malaysia has a strong oral tradition that has existed since before the arrival of writing and continues today.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.